Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
Peak Proteins are delighted that this paper, authors including our CEO, Dr Mark Abbott and Protein Purification Specialist Dr Raquel Faba Rodríguez, “Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity” has been published in the journal Viruses as part of the Special Issue SARS-CoV-2 Innate and Adaptive Immune Responses.
This work was funded by the Science Foundation Ireland COVID-19 Rapid Response Initiative and the project devised and lead by Dr William McCormack, Program Manager COVID-19 Immunology Project Trinity Translational Medicines Institute, Dr Gareth Brady PhD, Ussher Assistant Professor in Vascular Biology, Trinity Translational Medicine Institute and Thomas Phelan who is doing a PhD at the Trinity Translational Medicines Institute, Trinity College Dublin. Peak Proteins were asked to provide the full length SARS-CoV-2 Spike trimer, RBD and ACE2 receptor proteins for this work.
Abstract
Serological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determination of neutralization capacity within the assay protocol. Furthermore, commercial serology assays have a high buy-in cost that is inaccessible for many research groups. We have replicated the serological enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 antibody isotypes, developed at the Icahn School of Medicine at Mount Sinai, New York. Additionally, we have modified the protocol to include a neutralization assay with only a minor modification to this protocol. We used this assay to screen local COVID-19 patient sera (n = 91) and pre-COVID-19 control sera (n = 103), and obtained approximate parity with approved commercial anti-nucleoprotein-based assays with these sera. Furthermore, data from our neutralization assay closely aligns with that generated using a spike-based pseudovirus infection model when a subset of patient sera was analyzed.
